Stock Price Quote

WINDLAS BIOTECH LTD.

NSE : WINDLASBSE : 543329ISIN CODE : INE0H5O01029Industry : Pharmaceuticals & DrugsHouse : Private
BSE620.50-1.9 (-0.31 %)
PREV CLOSE ( ) 622.40
OPEN PRICE ( ) 620.95
BID PRICE (QTY) 616.00 (1)
OFFER PRICE (QTY) 620.50 (150)
VOLUME 13694
TODAY'S LOW / HIGH ( )606.20 623.15
52 WK LOW / HIGH ( )260 645
NSE620.70-1.55 (-0.25 %)
PREV CLOSE( ) 622.25
OPEN PRICE ( ) 621.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 620.70 (501)
VOLUME 60607
TODAY'S LOW / HIGH( ) 607.40 624.00
52 WK LOW / HIGH ( )260.1 648
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 19-02 2001
Management Info
Vivek Dhariwal - Chairman Hitesh Windlass - Managing Director
Registered Office

Address 40 / 1,Mohabewala Industrial Area,,
Dehradun,
Uttarakhand-248110

Phone 0135-6608000-30

Email grievance@windlasbiotech.com

Website www.windlasbiotech.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

04May Windlas Biotech informs about disclosu
Windlas Biotech has informed that the existing partnership firm ‘S S Kot..
29Apr Windlas Biotech informs about analyst
Pursuant to the relevant provisions of SEBI (Listing Obligations and Dis..
03Apr Windlas Biotech surges on commissionin
Windlas Biotech is currently trading at Rs. 562.85, up by 12.90 points o..
02Apr Windlas Biotech informs about press re
Windlas Biotech has informed that it attached press release on ‘Windlas..
02Apr Windlas Biotech commissions injectable
Windlas Biotech has commissioned its state-of-the-art injectable facilit..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit169.49581.44
Gross Profit 225.63 770.23
Operating Profit 263.75915.7
Net Sales 1712.856309.56

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Alkem Laboratories (BSE)
peergroup  5460.90 (2.86%)
M.Cap ( in Cr)65162.93
Glaxosmithkline Phar (BSE)
peergroup  2474.50 (4.09%)
M.Cap ( in Cr)41843.29
Gland Pharma (BSE)
peergroup  1880.90 (4.76%)
M.Cap ( in Cr)30949.11
Coral Laboratories (BSE)
peergroup  451.20 (20.00%)
M.Cap ( in Cr)161.20
Pfizer (BSE)
peergroup  4567.85 (1.64%)
M.Cap ( in Cr)20815.22

Shareholding Pattern

PROMOTERS 62.82%
NON-INSTITUTION 24.19%
MUTUAL FUNDS/UTI 10.37%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Windlas Biotech Ltd.

Windlas Biotech Ltd. was incorporated in the year 2001. Its today's share price is 620.5. Its current market capitalisation stands at Rs 1287.22 Cr. In the latest quarter, company has reported Gross Sales of Rs. 5130.83 Cr and Total Income of Rs.5230.48 Cr. The company's management includes Ananta Narayan Panda, Gaurav Gulati, Srinivasan Venkataraman, Vivek Dhariwal, Prachi Jain Windlass, Pawan Kumar Sharma, Manoj Kumar Windlass, Hitesh Windlass, Ashok Kumar Windlass.

It is listed on the BSE with a BSE Code of 543329 , NSE with an NSE Symbol of WINDLAS and ISIN of INE0H5O01029. It's Registered office is at 40 / 1,Mohabewala Industrial Area,Dehradun-248110, Uttarakhand. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are R Gupta & Associates, SS Kothari Mehta & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.